Patents by Inventor Siba K. Samal

Siba K. Samal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220402975
    Abstract: Provided are compositions and methods for vaccinating against picornaviruses. The compositions include modified Newcastle Disease viruses (NDVs) that are sufficient to produce virus-like particles (VLPs) in a host recipient. The modified NDVs contain a single stranded negative sense RNA polynucleotide having nucleotide sequences configured in a 3?-5? direction encoding sequentially NDV nucleocapsid protein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN) and RNA-dependent RNA polymerase (L) protein. A first nucleotide sequence encoding a picornavirus capsid polyprotein precursor is positioned between the between P and M nucleotide sequences. A second nucleotide sequence encoding a picornavirus protease that is capable of processing the capsid polyprotein precursor is positioned between the HN and L nucleotide sequences.
    Type: Application
    Filed: February 3, 2022
    Publication date: December 22, 2022
    Inventors: George Belov, Siba K. Samal, Ekaterina Viktorova
  • Publication number: 20190382450
    Abstract: Provided are compositions and methods for vaccinating against picornaviruses. The compositions include modified Newcastle Disease viruses (NDVs) that are sufficient to produce virus-like particles (VLPs) in a host recipient. The modified NDVs contain a single stranded negative sense RNA polynucleotide having nucleotide sequences configured in a 3?-5? direction encoding sequentially NDV nucleocapsid protein (NP), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin-neuraminidase (HN) and RNA-dependent RNA polymerase (L) protein. A first nucleotide sequence encoding a picornavirus capsid polyprotein precursor is positioned between the between P and M nucleotide sequences. A second nucleotide sequence encoding a picornavirus protease that is capable of processing the capsid polyprotein precursor is positioned between the HN and L nucleotide sequences.
    Type: Application
    Filed: June 17, 2019
    Publication date: December 19, 2019
    Inventors: George Belov, Siba K. Samal, Ekaterina Viktorova
  • Publication number: 20190358316
    Abstract: Provided are compositions and methods that involve recombinant Newcastle disease viruses (rNDVs) that contain an S protein of infectious bronchitis virus (IBV). The rNDV particles include a contiguous segment of IBV S protein that spans an IBV cleavage site between IBV SI and IBV S2 proteins, and can include a full length IBV S protein. Because the particles are multivalent they also stimulate a protective immune response against NDV infection. The compositions are particularly useful for use with avian animals, such as chickens. Isolated rNDV particles, and vaccine compositions that contain them are also provided.
    Type: Application
    Filed: February 6, 2018
    Publication date: November 28, 2019
    Inventors: Siba K. SAMAL, Edris SHIRVANI
  • Patent number: 10383936
    Abstract: In this study, for the first time, protective efficacy of gD against ILTV challenge was evaluated. Immunization with recombinant Newcastle disease virus expressing ILTV gD induced a higher level of neutralizing antibodies and offered complete protection to chickens against lethal ILTV challenge. Uses of recombinant NDV as a vaccine vector are also described.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: August 20, 2019
    Assignee: University of Maryland, College Park
    Inventors: Siba K. Samal, Mallikarjuna Kanabagatte Basavarajappa, Sweety Samal
  • Patent number: 9937196
    Abstract: In this application is described the complete genomic sequence of avian parmyxovirus type 2, strains Yucaipa, England, Kenya and Bangor. The sequences are useful for production of recombinant infective virus, a virus vector, for vaccine development and for therapeutic compositions.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: April 10, 2018
    Assignees: University of Maryland, College Park, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Siba K. Samal, Peter L. Collins
  • Patent number: 9803216
    Abstract: Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may be used in accordance with methods of providing enhanced oncolytic efficacy and delivering an oncolytic virus to tumors present in a patient. Also provided are methods for identifying a recombinant virus as an oncolytically-effective agent.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: October 31, 2017
    Assignee: University of Maryland
    Inventors: Elankumaran Subbiah, Siba K. Samal
  • Publication number: 20170049880
    Abstract: In this study, for the first time, protective efficacy of gD against ILTV challenge was evaluated. Immunization with recombinant Newcastle disease virus expressing ILTV gD induced a higher level of neutralizing antibodies and offered complete protection to chickens against lethal ILTV challenge. Uses of recombinant NDV as a vaccine vector are also described.
    Type: Application
    Filed: July 21, 2014
    Publication date: February 23, 2017
    Inventors: Siba k. SAMAL, Mallikarjuna kanabagatte BASAVARAJAPPA
  • Patent number: 9476033
    Abstract: The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more foreign genes inserted according to the invention, a cell containing the cDNA, a plasmid comprising the cDNA, a cell containing the plasmid, a cell containing the recombinant antigenomic RNA, and a recombinant NDV containing the recombinant antigenomic RNA of the invention, such as a recombinant NDV carrying one or more foreign genes recovered from transcription of the cDNA or the plasmid in a competent cell. The recombinant NDV carrying the one or more foreign genes can be used as a vaccine or vaccine vector.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: October 25, 2016
    Assignee: The University of Maryland, College Park
    Inventors: Siba K. Samal, Zhuhui Huang
  • Publication number: 20140186303
    Abstract: Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may be used in accordance with methods of providing enhanced oncolytic efficacy and delivering an oncolytic virus to tumors present in a patient. Also provided are methods for identifying a recombinant virus as an oncolytically-effective agent.
    Type: Application
    Filed: September 7, 2012
    Publication date: July 3, 2014
    Applicant: UNIVERSITY OF MARYLAND, COLLEGE PART,THE
    Inventors: Elankumaran Subbiah, Siba K. Samal
  • Publication number: 20120064112
    Abstract: The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more foreign genes inserted according to the invention, a cell containing the cDNA, a plasmid comprising the cDNA, a cell containing the plasmid, a cell containing the recombinant antigenomic RNA, and a recombinant NDV containing the recombinant antigenomic RNA of the invention, such as a recombinant NDV carrying one or more foreign genes recovered from transcription of the cDNA or the plasmid in a competent cell. The recombinant NDV carrying the one or more foreign genes can be used as a vaccine or vaccine vector.
    Type: Application
    Filed: July 21, 2011
    Publication date: March 15, 2012
    Applicant: THE UNIVERSITY OF MARYLAND, COLLEGE PARK
    Inventors: SIBA K. SAMAL, ZHUHUI HUANG
  • Publication number: 20110217266
    Abstract: In this application is described the complete genomic sequence of avian parmyxovirus type 2, strains Yucaipa, England, Kenya and Bangor. The sequences are useful for production of recombinant infective virus, a virus vector, for vaccine development and for therapeutic compositions.
    Type: Application
    Filed: June 21, 2010
    Publication date: September 8, 2011
    Inventors: Siba K. Samal, Peter L. Collins
  • Publication number: 20090175826
    Abstract: Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may be used in accordance with methods of providing enhanced oncolytic efficacy and delivering an oncolytic virus to tumors present in a patient. Also provided are methods for identifying a recombinant virus as an oncolytically-effective agent.
    Type: Application
    Filed: June 5, 2007
    Publication date: July 9, 2009
    Inventors: Elankumaran Subbiah, Siba K. Samal
  • Patent number: 7510863
    Abstract: The present invention is directed to novel avian pneumovirus strain Colorado (APV/CO) genes and intergenic sequences. Also disclosed are methods of making recombinant avian pneumovirus and live-attenuated APV/CO. Further disclosed are methods of diagnosing avian pneumovirus.
    Type: Grant
    Filed: June 16, 2004
    Date of Patent: March 31, 2009
    Assignee: University of Maryland, College Park
    Inventors: Siba K. Samal, Govindarajan Dhanasekaran
  • Patent number: 7244558
    Abstract: The present invention concerns cDNAs for making attentuated, infectious Newcastle disease virus (NDV). Another aspect of the invention relates to methods of making the cDNAs. Another aspect of the invention is a vector containing the cDNA optionally linked to an operable promoter. Within the scope of the invention are vaccines comprising the attenuated, infectious NDV. Also disclosed are methods of making the vaccines and methods of using the vaccines to prevent or treat Newcastle disease in an avian host. The present invention also concerns the nucleotide sequences of the entire genome of NDV, the leading region, the trailing region, and the NP region, as well as proteins encoded by these nucleotide sequences.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: July 17, 2007
    Assignees: University of Maryland, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Siba K. Samal, Peter L. Collins
  • Patent number: 6908618
    Abstract: A method of producing an attenuated bovine respiratory syncytial virus (BRSV) having increased or decreased transcription and/or replication, as compared to a wild-type BRSV, including the steps of inserting a synthetic cDNA which codes for an infectious BRSV into a host cell, wherein the cDNA is operably-linked to a promoter; expressing the cDNA in the host cell to produce the infectious BRSV; and thereafter introducing at least one site-specific RNA point mutation on the P gene of the BRSV. An attenuated BRSV and vaccine produced by the method are also included.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: June 21, 2005
    Assignee: University of Maryland
    Inventor: Siba K. Samal
  • Publication number: 20030224017
    Abstract: The present invention concerns an antigenomic RNA of Newcastle Disease virus (NDV) carrying one or more foreign genes inserted before NP gene, between P and M genes, and/or between HN and L genes. The invention is also directed toward a cDNA encoding a recombinant antigenomic RNA having one or more foreign genes inserted according to the invention, a cell containing the cDNA, a plasmid comprising the cDNA, a cell containing the plasmid, a cell containing the recombinant antigenomic RNA, and a recombinant NDV containing the recombinant antigenomic RNA of the invention, such as a recombinant NDV carrying one or more foreign genes recovered from transcription of the cDNA or the plasmid in a competent cell. The recombinant NDV carrying the one or more foreign genes can be used as a vaccine or vaccine vector.
    Type: Application
    Filed: May 19, 2003
    Publication date: December 4, 2003
    Inventors: Siba K. Samal, Zhuhui Huang
  • Publication number: 20030065158
    Abstract: A method of producing an attenuated bovine respiratory syncytial virus (BRSV) having increased or decreased transcription and/or replication, as compared to a wild-type BRSV, including the steps of inserting a synthetic cDNA which codes for an infectious BRSV into a host cell, wherein the cDNA is operably-linked to a promoter; expressing the cDNA in the host cell to produce the infectious BRSV; and thereafter introducing at least one site-specific RNA point mutation on the P gene of the BRSV. An attenuated BRSV and vaccine produced by the method are also included.
    Type: Application
    Filed: July 3, 2002
    Publication date: April 3, 2003
    Inventor: Siba K. Samal